| Michael C Catlin, MD | |
|
3366 Oakdale Ave N Ste 401, Robbinsdale, MN 55422-2986 | |
| (763) 520-2940 | |
| Not Available |
| Full Name | Michael C Catlin |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 8 Years |
| Location | 3366 Oakdale Ave N Ste 401, Robbinsdale, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144679143 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 71034 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Memorial Health | Robbinsdale, MN | Hospital |
| Maple Grove Hospital | Maple grove, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Memorial Health Care | 0042123028 | 483 |
| Respiratory Consultants Pa | 6204736853 | 17 |
News Archive
Improving water quality and hygiene practices may improve the growth of children, according to a new report. The Cochrane review – authored by the London School of Hygiene & Tropical Medicine and WaterAid – found evidence of small but significant improvements in growth of children under the age of five who have access to clean water and soap.
A new study by researchers at Weill Cornell Medical College shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal - such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.
Prana Biotechnology Limited has announced that it has identified novel therapeutic drug candidates from its Parkinson's disease program. Already, a lead candidate drug has demonstrated positive effects in pre-clinical studies, protecting the brain from damage to the substantia nigra, the area of the brain affected in Parkinson's disease.
Pharmacyclics, Inc. today announced the launch of informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy (CIT).
A methamphetamine epidemic rages across the United States with addicts blinded by uncontrollable desires for a drug that eventually thrusts them into a dire and catastrophic existence. Doctors don't have any effective treatments for these addicts, or for any other drug addicts; drug addiction is a disease that remains a medical mystery.
› Verified 3 days ago
| Entity Name | Respiratory Consultants Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356439277 PECOS PAC ID: 6204736853 Enrollment ID: O20040112000044 |
News Archive
Improving water quality and hygiene practices may improve the growth of children, according to a new report. The Cochrane review – authored by the London School of Hygiene & Tropical Medicine and WaterAid – found evidence of small but significant improvements in growth of children under the age of five who have access to clean water and soap.
A new study by researchers at Weill Cornell Medical College shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal - such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.
Prana Biotechnology Limited has announced that it has identified novel therapeutic drug candidates from its Parkinson's disease program. Already, a lead candidate drug has demonstrated positive effects in pre-clinical studies, protecting the brain from damage to the substantia nigra, the area of the brain affected in Parkinson's disease.
Pharmacyclics, Inc. today announced the launch of informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy (CIT).
A methamphetamine epidemic rages across the United States with addicts blinded by uncontrollable desires for a drug that eventually thrusts them into a dire and catastrophic existence. Doctors don't have any effective treatments for these addicts, or for any other drug addicts; drug addiction is a disease that remains a medical mystery.
› Verified 3 days ago
| Entity Name | North Memorial Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851344907 PECOS PAC ID: 0042123028 Enrollment ID: O20040122000470 |
News Archive
Improving water quality and hygiene practices may improve the growth of children, according to a new report. The Cochrane review – authored by the London School of Hygiene & Tropical Medicine and WaterAid – found evidence of small but significant improvements in growth of children under the age of five who have access to clean water and soap.
A new study by researchers at Weill Cornell Medical College shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal - such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.
Prana Biotechnology Limited has announced that it has identified novel therapeutic drug candidates from its Parkinson's disease program. Already, a lead candidate drug has demonstrated positive effects in pre-clinical studies, protecting the brain from damage to the substantia nigra, the area of the brain affected in Parkinson's disease.
Pharmacyclics, Inc. today announced the launch of informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy (CIT).
A methamphetamine epidemic rages across the United States with addicts blinded by uncontrollable desires for a drug that eventually thrusts them into a dire and catastrophic existence. Doctors don't have any effective treatments for these addicts, or for any other drug addicts; drug addiction is a disease that remains a medical mystery.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael C Catlin, MD 2800 Campus Dr Ste 10, Plymouth, MN 55441-2669 Ph: (763) 520-2940 | Michael C Catlin, MD 3366 Oakdale Ave N Ste 401, Robbinsdale, MN 55422-2986 Ph: (763) 520-2940 |
News Archive
Improving water quality and hygiene practices may improve the growth of children, according to a new report. The Cochrane review – authored by the London School of Hygiene & Tropical Medicine and WaterAid – found evidence of small but significant improvements in growth of children under the age of five who have access to clean water and soap.
A new study by researchers at Weill Cornell Medical College shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal - such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.
Prana Biotechnology Limited has announced that it has identified novel therapeutic drug candidates from its Parkinson's disease program. Already, a lead candidate drug has demonstrated positive effects in pre-clinical studies, protecting the brain from damage to the substantia nigra, the area of the brain affected in Parkinson's disease.
Pharmacyclics, Inc. today announced the launch of informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy (CIT).
A methamphetamine epidemic rages across the United States with addicts blinded by uncontrollable desires for a drug that eventually thrusts them into a dire and catastrophic existence. Doctors don't have any effective treatments for these addicts, or for any other drug addicts; drug addiction is a disease that remains a medical mystery.
› Verified 3 days ago
Dr. Alok Maheshwari, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-581-5400 Fax: 763-581-5401 | |
Hani Al Salti Al Krad, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-520-5200 | |
Ethan Michael Fruechte, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Suite 200, Robbinsdale, MN 55422 Phone: 763-581-5400 Fax: 763-520-2099 | |
Matthew Nolan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3366 Oakdale Ave N Ste 401, Robbinsdale, MN 55422 Phone: 763-520-2940 | |
Jerrold Martin Stempel, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 3366 Oakdale Ave N, Suite 315, Robbinsdale, MN 55422 Phone: 763-520-7900 Fax: 763-520-7989 | |
Chike Uchenna Anthony Obi, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-581-5400 Fax: 763-581-5401 | |
Dr. John Manion, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 3435 West Broadway, Suite 1065, Robbinsdale, MN 55422 Phone: 763-520-1137 Fax: 763-520-1976 |